HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of the iodine-free computed tomography liver contrast agent, Dy-EOB-DTPA, in comparison with a conventional iodinated agent in normal and in tumor-bearing rabbits.

AbstractRATIONALE AND OBJECTIVES:
To investigate the efficacy of the new liver-specific x-ray contrast agent, Dy-EOB-DTPA, in rabbits with VX2 liver tumors by spiral computed tomography (CT) in comparison to iopromide.
MATERIALS AND METHODS:
The time course of liver enhancement was determined in five groups of two normal anesthetized rabbits, which received intravenous injections of Dy-EOB-DTPA before anesthesia at a dose of 0.5 mmol/kg. Fifteen, 30, 45, 60, and 90 minutes after administration spiral CT images were obtained and the attenuation in the livers were determined. A second group of ten rabbits with implanted VX2 tumors received in a random crossover design either Dy-EOB-DTPA at a dose of 0.5 mmol/kg or, 1 day later, iopromide at a dose of 600 mg iodine/kg. CT images were obtained 60 minutes after Dy-EOB-DTPA administration and both in the arterial and portal-venous phases after iopromide injection. Three radiologists evaluated the images. The rabbits were killed, and their livers were investigated histologically for liver tumors.
RESULTS:
In normal animals, 0.5 mmol/kg Dy-EOB-DTPA resulted in a liver enhancement of 30 HU during the whole observation period of 90 minutes. In tumor-bearing animals, histology revealed 14 implanted tumors of 3-20 mm diameter. Sixty-five percent of the tumors were below 10 mm. Dy-EOB-DTPA was able to detect 13 tumors (93%), iopromide 11 (79%) both in the arterial and in the portal-venous phase. The difference was statistically not significant. In plain CT, seven tumors (50%) were found (P < 0.01 vs iopromide and Dy-EOB-DTPA). One scar and two sites of necrosis were detected by each of the methods.
CONCLUSION:
Dy-EOB-DTPA injection at a dose of 0.5 mmol/kg resulted in a long-lasting detectability of 93% of all implanted tumors versus 79% found with iopromide.
AuthorsWerner Krause, Kerstin Handreke, G Schuhmann-Giampieri, K Rupp
JournalInvestigative radiology (Invest Radiol) Vol. 37 Issue 5 Pg. 241-7 (May 2002) ISSN: 0020-9996 [Print] United States
PMID11979149 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Contrast Media
  • dysprosium ethoxybenzyl DTPA
  • Iohexol
  • iopromide
  • Pentetic Acid
Topics
  • Animals
  • Contrast Media (administration & dosage, pharmacokinetics)
  • Injections, Intravenous
  • Iohexol (administration & dosage, analogs & derivatives)
  • Liver (diagnostic imaging, metabolism)
  • Liver Neoplasms, Experimental (diagnostic imaging, metabolism, pathology)
  • Molecular Structure
  • Pentetic Acid (administration & dosage, analogs & derivatives, chemistry, pharmacokinetics)
  • Rabbits
  • Time Factors
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: